| Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera H Gisslinger, O Zagrijtschuk, V Buxhofer-Ausch, J Thaler, E Schloegl, ... Blood, The Journal of the American Society of Hematology 126 (15), 1762-1769, 2015 | 196 | 2015 |
| A modified scoring of the NCCN‐IPI is more accurate in the elderly and is improved by albumin and β2‐microglobulin T Melchardt, K Troppan, L Weiss, C Hufnagl, D Neureiter, ... British journal of haematology 168 (2), 239-245, 2015 | 90 | 2015 |
| Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia L Weiss, T Melchardt, A Egle, C Grabmer, R Greil, I Tinhofer Cancer 117 (10), 2163-2169, 2011 | 73 | 2011 |
| Azacitidine in patients with WHO-defined AML–results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group L Pleyer, R Stauder, S Burgstaller, M Schreder, C Tinchon, M Pfeilstocker, ... Journal of hematology & oncology 6, 1-13, 2013 | 72 | 2013 |
| Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases AS Berghoff, A Ilhan‐Mutlu, C Dinhof, M Magerle, M Hackl, G Widhalm, ... Neuropathology and applied neurobiology 41 (2), e41-e55, 2015 | 66 | 2015 |
| αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer AS Berghoff, AK Kovanda, T Melchardt, R Bartsch, JA Hainfellner, B Sipos, ... Clinical & experimental metastasis 31, 841-851, 2014 | 66 | 2014 |
| C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients KT Troppan, K Schlick, A Deutsch, T Melchardt, A Egle, T Stojakovic, ... British journal of cancer 111 (1), 55-60, 2014 | 63 | 2014 |
| Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b NCC Them, K Bagienski, T Berg, B Gisslinger, M Schalling, D Chen, ... American Journal of Hematology 90 (4), 288-294, 2015 | 62 | 2015 |
| Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases AS Berghoff, A Ilhan-Mutlu, M Preusser, A Woehrer, JA Hainfellner, ... Strahlentherapie und Onkologie 190, 2014 | 62 | 2014 |
| A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma B Kiesewetter, E Willenbacher, W Willenbacher, A Egle, P Neumeister, ... Blood, The Journal of the American Society of Hematology 129 (3), 383-385, 2017 | 59 | 2017 |
| Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial G Hopfinger, T Nösslinger, A Lang, W Linkesch, T Melchardt, L Weiss, ... Annals of hematology 93, 459-462, 2014 | 58 | 2014 |
| Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy … R Greil, P Obrtlíková, L Smolej, T Kozák, M Steurer, J Andel, S Burgstaller, ... The Lancet Haematology 3 (7), e317-e329, 2016 | 55 | 2016 |
| Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma L Weiss, T Melchardt, S Habringer, A Boekstegers, C Hufnagl, D Neureiter, ... Annals of oncology 25 (1), 171-176, 2014 | 54 | 2014 |
| Prognostic and predictive factors in advanced head and neck squamous cell carcinoma T Magnes, S Wagner, D Kiem, L Weiss, G Rinnerthaler, R Greil, ... International journal of molecular sciences 22 (9), 4981, 2021 | 50 | 2021 |
| Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones T Melchardt, C Hufnagl, DM Weinstock, N Kopp, D Neureiter, ... Oncotarget 7 (32), 51494, 2016 | 50 | 2016 |
| Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib L Kazianka, C Drucker, C Skrabs, W Thomas, T Melchardt, S Struve, ... Leukemia 31 (5), 1117-1122, 2017 | 45 | 2017 |
| NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients KT Prochazka, T Melchardt, F Posch, K Schlick, A Deutsch, ... British Journal of Cancer 115 (10), 1264-1272, 2016 | 45 | 2016 |
| Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia FJ Gassner, N Zaborsky, D Neureiter, M Huemer, T Melchardt, A Egle, ... Haematologica 99 (5), 67, 2014 | 44 | 2014 |
| Independent prognostic value of serum markers in diffuse large B-cell lymphoma in the era of the NCCN-IPI T Melchardt, K Troppan, L Weiss, C Hufnagl, D Neureiter, ... Journal of the National Comprehensive Cancer Network 13 (12), 1501-1508, 2015 | 43 | 2015 |
| Viral infections and their management in patients with chronic lymphocytic leukemia T Melchardt, L Weiss, R Greil, A Egle Leukemia & lymphoma 54 (8), 1602-1613, 2013 | 43 | 2013 |
